MEGIN Announces Sale of TRIUX™ neo to University of Nebraska Medical Center

MEGIN announced the purchase of their fourth-generation magnetoencephalography (MEG) technology, the c, by the University of Nebraska Medical Center (UNMC).

UNMC scientists and clinicians are at the leading edge of medical discovery and breakthroughs, transforming lives across the state and around the world. Their state-of-the-art facilities enable UNMC graduate and medical students, residents, fellows, and faculty to study and work in a technologically enhanced academic research environment.

The Omaha campus is home to more than 740,000 square feet of dedicated research space and offers dozens of shared technologies and services.

MEGIN’s TRIUX™ neo is a highly sensitive technology that can accurately detect and localize neural events that are generated in the brain with exquisite resolution. The TRIUX™ neo offers the most precise functional information currently available on the market for functional brain imaging in children, adolescents and adults.

MEGIN advises the UNMC/Nebraska Medicine started using MEG in 2009 and was one of the first institutions to use the device in the United States. UNCM’s MEG Laboratory plans to use MEGIN’s non-invasive MEG technology for both clinical services and research initiatives.

“Using this new technology, we expect to provide state-of-the art MEG diagnostic services to patients with the most difficult cases of epilepsy, for years to come, in collaboration with all major epilepsy center in the region. Patients, including young children, will receive the most accurate available presurgical anatomical brain mapping of the language, motor, sensory, visual and auditory functions, which is critical for effective surgical planning,” explains Dr. Valentina Gumenyuk, Assistant Professor, Department of Neurological Sciences at UNMC.

UNMC researchers lead by Dr. Olga Taraschenko, Director of the Comprehensive Epilepsy Center, will use MEG to identify patterns of functional brain connectivity in patients with severe epilepsy, including those referred for surgery, to determine how their seizures may affect brain connections and cognition.

The MEG will also be deployed in clinical and translational research studies to diagnose brain tumors, in collaboration with UNMC’s Buffet Cancer Center and UNMC Department of Neurosurgery lead by Dr. Aviva Abosch, renowned functional neurosurgeon. Another innovative effort will use MEG to identify early biomarkers for specific types of dementia such as Alzheimer’s Disease, Lewy Body Disease, and Frontotemporal Dementia, to increase opportunities for early treatment, and to study sleep related abnormalities in these patients.

“The new MEG device is another arrow in our marvelous quiver of technologies and tools to help advance discovery of brain mechanisms as targets for new treatments and cures for the patients, families and communities we serve,” says Dr. Matthew Rizzo, Chair of the Department of Neurological Sciences at UNMC.

SourceMEGIN
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."
Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers. Our aim is to make Perimeter's innovative technology the standard of care in cancer surgery."

By using this website you agree to accept Medical Device News Magazine Privacy Policy